These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 15126649

  • 21. [Efficacy and safety of lanthanum carbonate in chronic kidney disease patients with hyperphosphataemia].
    Laville M.
    Nephrol Ther; 2011 Jun; 7(3):154-61. PubMed ID: 21247818
    [Abstract] [Full Text] [Related]

  • 22. Managing mineral balance in end-stage renal disease.
    Ritz E.
    Nephrol Dial Transplant; 2004 Mar; 19 Suppl 1():i1-3. PubMed ID: 15126646
    [No Abstract] [Full Text] [Related]

  • 23. Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate.
    Hutchison AJ, Speake M, Al-Baaj F.
    Nephrol Dial Transplant; 2004 Jul; 19(7):1902-6. PubMed ID: 15199195
    [Abstract] [Full Text] [Related]

  • 24. A possible non-aluminum oral phosphate binder? A comparative study on dietary phosphorus absorption.
    Graff L, Burnel D.
    Res Commun Mol Pathol Pharmacol; 1995 Sep; 89(3):373-88. PubMed ID: 8680806
    [Abstract] [Full Text] [Related]

  • 25. Lanthanum: a safe phosphate binder.
    Persy VP, Behets GJ, Bervoets AR, De Broe ME, D'Haese PC.
    Semin Dial; 2006 Sep; 19(3):195-9. PubMed ID: 16689967
    [Abstract] [Full Text] [Related]

  • 26. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
    Shaheen FA, Akeel NM, Badawi LS, Souqiyyeh MZ.
    Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212
    [Abstract] [Full Text] [Related]

  • 27. Long-term treatment with lanthanum carbonate reduces mineral and bone abnormalities in rats with chronic renal failure.
    Damment S, Secker R, Shen V, Lorenzo V, Rodriguez M.
    Nephrol Dial Transplant; 2011 Jun; 26(6):1803-12. PubMed ID: 21098011
    [Abstract] [Full Text] [Related]

  • 28. Lanthanum carbonate: time to abandon prejudices?
    Brancaccio D, Cozzolino M.
    Kidney Int; 2007 Feb; 71(3):190-2. PubMed ID: 17252028
    [Abstract] [Full Text] [Related]

  • 29. Blast from the past: the aluminum's ghost on the lanthanum salts.
    Canavese C, Mereu C, Nordio M, Sabbioni E, Aime S.
    Curr Med Chem; 2005 Feb; 12(14):1631-6. PubMed ID: 16022663
    [Abstract] [Full Text] [Related]

  • 30. Control of hyperphosphatemia among patients with ESRD.
    Coladonato JA.
    J Am Soc Nephrol; 2005 Nov; 16 Suppl 2():S107-14. PubMed ID: 16251245
    [Abstract] [Full Text] [Related]

  • 31. Phosphate binders in chronic kidney disease and end-stage renal disease: a patient-centered approach.
    Novak JE, Szczech LA.
    Semin Dial; 2009 Nov; 22(1):56-63. PubMed ID: 19000107
    [Abstract] [Full Text] [Related]

  • 32. Development and reversibility of impaired mineralization associated with lanthanum carbonate treatment in chronic renal failure rats.
    Bervoets AR, Oste L, Behets GJ, Dams G, Blust R, Marynissen R, Geryl H, De Broe ME, D'Haese PC.
    Bone; 2006 Jun; 38(6):803-10. PubMed ID: 16412714
    [Abstract] [Full Text] [Related]

  • 33. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients.
    Voormolen N, Noordzij M, Grootendorst DC, Beetz I, Sijpkens YW, van Manen JG, Boeschoten EW, Huisman RM, Krediet RT, Dekker FW, PREPARE study group.
    Nephrol Dial Transplant; 2007 Oct; 22(10):2909-16. PubMed ID: 17517792
    [Abstract] [Full Text] [Related]

  • 34. Calcium-based phosphate binders are appropriate in chronic renal failure.
    Friedman EA.
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):704-9. PubMed ID: 17699276
    [Abstract] [Full Text] [Related]

  • 35. [Introduction to lanthanum carbonate: pharmacology, safety and tolerability].
    Rodríguez Portillo M.
    Nefrologia; 2008 Jul; 28 Suppl 5():7-10. PubMed ID: 18847413
    [Abstract] [Full Text] [Related]

  • 36. Cinacalcet: new drug. Secondary hyperparathyroidism: where are the clinical data?
    Prescrire Int; 2006 Jun; 15(83):90-3. PubMed ID: 16764095
    [Abstract] [Full Text] [Related]

  • 37. [Iatrogenic aluminum osteopathy in a uremic infant].
    Koch H, Reich H, Franke D, Delling G.
    Monatsschr Kinderheilkd; 1986 May; 134(5):279-81. PubMed ID: 3724766
    [Abstract] [Full Text] [Related]

  • 38. Lanthanum Carbonate - A New Phosphate Binding Drug in Advanced Renal Failure.
    Aaseth J, Bjorke-Monsen AL.
    Curr Med Chem; 2018 May; 25(1):113-117. PubMed ID: 28486924
    [Abstract] [Full Text] [Related]

  • 39. REFOS study: efficacy and safety of lanthanum carbonate in clinical practice in Spain.
    Torregrosa JV, González-Parra E, González MT, Cannata-Andía J.
    Nefrologia; 2014 May 21; 34(3):360-8. PubMed ID: 24849057
    [Abstract] [Full Text] [Related]

  • 40. Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate.
    Behets GJ, Verberckmoes SC, Oste L, Bervoets AR, Salomé M, Cox AG, Denton J, De Broe ME, D'Haese PC.
    Kidney Int; 2005 May 21; 67(5):1830-6. PubMed ID: 15840030
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.